All donations up to $200,000 matched before June 30 Donate
In this webinar designed for patients and caregivers, Ariella Chivil, a patient advocate, and Alexander M. Lesokhin, M.D., her oncologist, discuss the nuances of communicating and informing both doctor and patient while on immunotherapy.
Dr. John Bell of the University of Ottawa and the Ontario Institute for Cancer Research discussses strategies that re-program viruses so that they selectively infect and kill cancer cells while leaving healthy cells and tissues unharmed.
In this webinar designed for patients and caregivers, two patients share their experiences with cancer immunotherapy as well as share advice for patients currently seeking or receiving immunotherapy treatment.
Patrick Meins of EmergingMed will answer common questions around cancer clinical trials including trial definitions, eligibility criteria, and how to search for the right one.
Dr. James P. Allison of MD Anderson discusses how some proteins in immune cells act as "brakes" on the immune system response and how checkpoint inhibitors can be used to “release the brakes,” allowing a stronger immune attack against cancer.
Dr. Jedd D. Wolchok of Memorial Sloan Kettering Cancer Center discusses the latest developments in patient care including: checkpoint blockade, cancer vaccines, combination therapies, CAR T cell therapy, T cell receptor therapies, and neoantigens.
Dr. John B. Liao of the University of Washington discusses the immunotherapy landscape for patients with ovarian cancer.
Dr. Dustin A. Deming of the University of Wisconsin Carbone Cancer Center discusses the most effective immunotherapies currently available to patients with stomach, gastrointestinal (GI), and colorectal (CRC) cancers.
Dr. Robert D. Schreiber of of Washington University School of Medicine in St. Louis discusses how advances in our understanding of genomics have enabled doctors to identify the mutations driving individual tumors.
Dr. Hearn Jay Cho of the Mt. Sinai School of Medicine discusses the latest research and developments in cancer immunotherapy for leukemia, lymphoma, and multiple myeloma.
Dr. Haidong Dong of the Mayo Clinic discusses the role biomarkers play in making treatment decisions and delves into the latest research to identify new biomarkers.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, 4th Floor | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
Cancer Research Institute held its annual Through the Kitchen benefit party yesterday evening and raised $1.4 million to fund six promising postdoctoral fellows over three years.
A second CAR T cell immunotherapy targeting the CD19 receptor was approved by the FDA for patients with relapsed or refractory large B cell lymphoma.